Pneumococcal Vaccination Induces Antibody Responses in Patients With Multiple Myeloma
A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.
Multiple Myeloma
Treatment With Daratumumab for Multiple Myeloma May Improve Quality of Life
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
Subcutaneous Daratumumab Associated With Higher Patient Satisfaction, Drastically Fewer Infusion Reactions Than Intravenous Formulations
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Once-Weekly Carfilzomib Is Tolerable in Patients With Relapsed/Refractory Multiple Myeloma
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Carfilzomib for Relapsed and Refractory Multiple Myeloma
[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.
Lenalidomide Shown to Reduce the Risk of Progression in Smoldering Multiple Myeloma
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Autologous Stem Cell Transplantation Challenged by Emerging Pharmacotherapies in Multiple Myeloma
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
Triplet Therapy for Relapsed or Refractory Multiple Myeloma May Improve Clinical Outcomes
Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.
Next post in Multiple Myeloma
